MedTrace Logo

XEN1101 for Major Depressive Disorder

NCT04827901 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-04-02

No results posted yet for this study

Summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

Conditions

Interventions

DRUG

XEN1101

two 10 mg capsules

DRUG

Placebo

matching placebo

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • James Murrough

    lead OTHER

Principal Investigators

  • James W Murrough, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2024-10-03
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827901 on ClinicalTrials.gov